Universe Pharmaceuticals INC (UPC) Key Metrics
UPC valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $19.7M
- Enterprise value
- $4.1M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 1.1
- Price / book
- 0.4
- EV / EBITDA
- 0.3
- Dividend yield
- —
- Beta
- 1.68
UPC key metrics, FY2018–FY2025
Fiscal year ended September 30, 2025 · U.S. dollarsUPC returns How much profit the business earns on the capital it uses.
UPC financial health Debt, liquidity and how easily interest is covered.
UPC efficiency & capital use Working capital cycle and where the cash goes.
UPC returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
UPC debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
UPC cash returned to shareholders
UPC key metrics
FY2018–FY2025| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | |
|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||
| Share price at fiscal year-end | $4.20 | $146.40 | $570.00 | $339.00 | $1,482.00 | — | — | — |
| Returns & profitability | ||||||||
| Return on equity (ROE) | −7.2% | −20.5% | −14.3% | −16.6% | 28.4% | 45.5% | 68.4% | 78.5% |
| Return on invested capital (ROIC) | −9.2% | −28.4% | −9.6% | −15.2% | 41.0% | 61.1% | 85.5% | 126.2% |
| Return on assets (ROA) | −5.4% | −14.4% | −10.9% | −13.5% | 22.9% | 32.4% | 32.9% | 27.1% |
| Return on tangible assets | −5.3% | −12.9% | −11.6% | −14.7% | 16.2% | 26.4% | 42.7% | 27.3% |
| Free cash flow margin | −30.2% | −42.9% | 3.3% | −3.5% | −32.5% | 19.7% | 39.5% | 15.1% |
| Income quality (OCF / net income) | — | — | — | — | −0.18 | 0.81 | 1.75 | 0.59 |
| Financial health | ||||||||
| Total debt | $9.3M | $2.1M | $5.5M | $3.9M | $4.3M | $2.6M | $2.5M | $2.6M |
| Cash & short-term investments | $33.6M | $29.5M | $18.5M | $18.9M | $21.8M | $10.1M | $3.2M | $6.2M |
| Net debt | −$24.3M | −$27.4M | −$13.0M | −$14.9M | −$17.5M | −$7.4M | −$655,521 | −$3.6M |
| Debt / equity | 0.16 | 0.05 | 0.14 | 0.08 | 0.07 | 0.13 | 0.20 | 0.27 |
| Debt / assets | 0.13 | 0.03 | 0.10 | 0.07 | 0.06 | 0.09 | 0.14 | 0.09 |
| Net debt / EBITDA | — | — | — | — | −1.23 | −0.70 | −0.06 | −0.35 |
| Current ratio | 4.07 | 2.54 | 2.68 | 3.17 | 4.50 | 2.85 | 2.24 | 1.19 |
| Quick ratio | 3.90 | 2.46 | 2.43 | 3.00 | 4.28 | 2.62 | 1.76 | 0.75 |
| Interest coverage | -12.6 | -28.8 | -22.5 | -43.2 | 133.8 | 82.8 | 75.4 | 58.6 |
| Working capital | $40.4M | $31.3M | $23.1M | $28.4M | $39.3M | $14.8M | $6.8M | $3.6M |
| Invested capital | $31.8M | $18.1M | $26.5M | $31.5M | $41.5M | $13.4M | $11.7M | $6.1M |
| Tangible asset value | $55.8M | $45.2M | $39.4M | $46.3M | $58.8M | $20.6M | $12.2M | $9.5M |
| Net current asset value | $40.4M | $29.2M | $23.1M | $28.4M | $39.3M | $14.8M | $6.8M | $3.6M |
| Capital allocation | ||||||||
| Dividends paid | — | — | — | $0 | $0 | $0 | $16.0M | $3.1M |
| Dividend payout ratio | — | — | — | — | 0.0% | 0.0% | 211.9% | 40.2% |
| Dividends + buybacks / free cash flow | — | — | — | — | — | 0.0% | 122.0% | 71.0% |
| Capex / revenue | 1.9% | 1.6% | 0.1% | 0.2% | 28.2% | 0.2% | 0.3% | 0.5% |
| Capex / operating cash flow | — | — | 3.9% | — | — | 0.8% | 0.7% | 3.3% |
| Capex / depreciation | 0.67 | 0.75 | 0.09 | 0.18 | 30.28 | 0.13 | 0.21 | 0.32 |
| R&D / revenue | 3.8% | 15.6% | 15.0% | 19.0% | 11.4% | 1.9% | 1.9% | 2.8% |
| SG&A / revenue | 44.8% | 42.9% | 27.9% | 53.0% | 13.1% | 9.1% | 6.9% | 8.4% |
| Efficiency | ||||||||
| Days sales outstanding | 266.6 | 187.3 | 146.4 | 140.9 | 101.5 | 102.8 | 77.2 | 97.8 |
| Days of inventory on hand | 62.1 | 54.7 | 46.1 | 46.7 | 35.2 | 49.7 | 98.8 | 196.2 |
| Days payables outstanding | 104.0 | 102.3 | 63.6 | 83.9 | 64.5 | 50.9 | 44.9 | 71.0 |
| Cash conversion cycle (days) | 224.7 | 139.8 | 128.9 | 103.7 | 72.2 | 101.6 | 131.2 | 223.0 |
| Receivables turnover | 1.37 | 1.95 | 2.49 | 2.59 | 3.60 | 3.55 | 4.73 | 3.73 |
| Payables turnover | 3.51 | 3.57 | 5.74 | 4.35 | 5.66 | 7.18 | 8.13 | 5.14 |
| Inventory turnover | 5.88 | 6.67 | 7.93 | 7.82 | 10.37 | 7.35 | 3.69 | 1.86 |
| Asset turnover | 0.26 | 0.38 | 0.57 | 0.62 | 0.97 | 1.32 | 1.45 | 1.02 |
| Average receivables | $13.0M | $11.8M | $13.0M | $15.5M | $13.3M | $8.6M | $7.0M | $7.6M |
| Average payables | $3.3M | $4.8M | $3.8M | $4.2M | $4.0M | $2.3M | $2.4M | $2.9M |
| Average inventory | $2.0M | $2.5M | $2.8M | $2.3M | $2.2M | $2.3M | $5.4M | $8.1M |
| Intangibles / total assets | 0.4% | 0.4% | 0.3% | 0.3% | 0.3% | 0.6% | 1.0% | 0.7% |
Computed from UPC's annual financial statements (latest annual report filed January 29, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
UPC valuation and financial ratios
Universe Pharmaceuticals INC earned a return on equity of −7.2% and a return on invested capital of −9.2% in fiscal 2025. It ended the year with $9.3 million of debt and $33.6 million in cash and short-term investments, a net cash position of $24.3 million.
See the UPC income statement, the UPC chart for price history, or the UPC stock overview for the latest quote and news.
UPC key metrics FAQ
What is Universe Pharmaceuticals INC's return on equity?
Universe Pharmaceuticals INC's return on equity (ROE) was −7.2% in fiscal 2025: net income of -$3.7 million on average shareholders' equity of $50.8 million.
What is Universe Pharmaceuticals INC's ROIC?
Universe Pharmaceuticals INC's return on invested capital was −9.2% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Universe Pharmaceuticals INC have?
Universe Pharmaceuticals INC had total debt of $9.3 million at the end of fiscal 2025, a debt-to-equity ratio of 0.16 and more cash than debt.
What is Universe Pharmaceuticals INC's current ratio?
Universe Pharmaceuticals INC's current ratio was 4.07 at the end of fiscal 2025: current assets were 4.07 times current liabilities.